New York, April 28, 2016 -- Moody's Investors Service said that Abbott Laboratories' A2 senior unsecured and Prime-1 short-term ratings remain on review for downgrade. This follows the news that the company has signed a definitive agreement to acquire St. Jude Medical, Inc. for about $31 billion (including St Jude's $5.7 billion of net debt). Abbott's ratings were initially placed on review on February 1, 2016 when Abbott announced plans to acquire Alere, Inc., a diagnostics manufacturer, for $8.4 billion.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.